{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:33Z","timestamp":1787653173264,"version":"build-2736575974"},"reference-count":22,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100011009","name":"International Society of Oncology Pharmacy Practitioners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>This study assessed the impact of a targeted training program offered by the International Society of Oncology Pharmacy Practitioners in enhancing biosimilar knowledge among healthcare professionals at the University of Ilorin Teaching Hospital, Nigeria, addressing the critical need for cost-effective cancer care. An interventional, pre- and post-test design was employed, involving 24 healthcare professionals comprising of 16 physicians, 3 pharmacists, and 5 nurses. Participants underwent a one-day training session focused on biologics, biosimilars, and their clinical applications in cancer care, delivered by trained oncology pharmacists. Comparison of pre- and post-training knowledge was assessed using a standardized questionnaire. Statistical analysis, including descriptive statistics and paired t-tests, was conducted to evaluate the impact of the intervention.<\/jats:p>\n                  <jats:p>\n                    Results demonstrated a significant improvement in biosimilar knowledge following the training. The mean (\u00b1SD) post-test score (7.3\u2009\u00b1\u20093.0) was significantly higher than the mean pre-test score (4.6\u2009\u00b1\u20092.3), with a 2.7-point increase (p\u2009&lt;\u20090.001). Despite participants\u2019 professional experience, baseline knowledge was notably low compared to the post-test. The training program effectively bridged this knowledge gap, indicating its potential to facilitate biosimilar adoption. This study concludes that targeted training significantly enhances healthcare professionals\u2019 understanding of biosimilars. Continued education and training are crucial to optimizing biosimilar implementation and improving access to affordable cancer care in resource-limited settings\n                    <jats:bold>.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1177\/10781552261428431","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T14:20:42Z","timestamp":1774102842000},"page":"1168-1173","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of healthcare providers\u2019 training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5779-3138","authenticated-orcid":false,"given":"Modupe Lydia","family":"Olarewaju","sequence":"first","affiliation":[{"name":"University of Ilorin Teaching Hospital"},{"name":"University of Ilorin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheem Bolanle","family":"Rahamon","sequence":"additional","affiliation":[{"name":"University of Ilorin Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4468-4518","authenticated-orcid":false,"given":"Oluwabusayo","family":"Abolarin","sequence":"additional","affiliation":[{"name":"University of Ilorin Teaching Hospital"},{"name":"University of Ilorin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1362-141X","authenticated-orcid":false,"given":"Temitope Kemi","family":"Asishana","sequence":"additional","affiliation":[{"name":"University of Ilorin Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapheal","family":"Ibregbe","sequence":"additional","affiliation":[{"name":"University of Ilorin Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4391-4219","authenticated-orcid":false,"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"01","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong L","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021; 6: 01.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_3_2","unstructured":"European Medicines Agency. Biosimilars in the EU: Information guide for healthcare professionals by European Medicines Agency and the European Commission 2019. [Accessed 03 Nov 2024]."},{"key":"e_1_3_3_4_2","first-page":"133","article-title":"Review of biosimilars and their potential use in oncology treatment and supportive care in the United States","volume":"9","author":"Pittman WL","year":"2019","unstructured":"Pittman WL, Wern C, Glode AE. Review of biosimilars and their potential use in oncology treatment and supportive care in the United States. JHOP 2019; 9: 133\u2013141.","journal-title":"JHOP"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00659-0"},{"key":"e_1_3_3_6_2","first-page":"45","article-title":"Implementation strategies of biosimilars in healthcare systems: the path forward","volume":"15","author":"Raymond KC","year":"2022","unstructured":"Raymond KC, Stewart AL, Edgerton CC, et al. Implementation strategies of biosimilars in healthcare systems: the path forward. Am Health Drug Benefits 2022; 15: 45\u201353.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165800"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0207-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220913098"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219893441"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00460-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2022.137019"},{"key":"e_1_3_3_13_2","article-title":"Knowledge on the use of biosimilars in hematological malignancies amongst healthcare workers at a tertiary hospital in northeast Nigeria","volume":"40","author":"Dachi AR","year":"2023","unstructured":"Dachi AR, Maryam M, Nura HA, et al. Knowledge on the use of biosimilars in hematological malignancies amongst healthcare workers at a tertiary hospital in northeast Nigeria. West Afr J Med 2023; 40: S26.","journal-title":"West Afr J Med"},{"key":"e_1_3_3_14_2","unstructured":"University of Ilorin Teaching Hospital Website. [accessed on 8 April 2024] Available from https:\/\/www.uithilorin.org.ng."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-021-00330-x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.1.102"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.1061"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom9020057"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.876503"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00771"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034183"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70234"},{"key":"e_1_3_3_23_2","first-page":"240","article-title":"Strategies and ethics to ensure equitable access to biological medicines in the treatment of autoimmune inflammatory diseases","volume":"31","author":"Hodkinson B","year":"2018","unstructured":"Hodkinson B, Blockman M. Strategies and ethics to ensure equitable access to biological medicines in the treatment of autoimmune inflammatory diseases. Allergy Society of South Africa (ALLSA) 2018; 31: 240\u2013244.","journal-title":"Allergy Society of South Africa (ALLSA)"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261428431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261428431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261428431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:31:38Z","timestamp":1787650298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261428431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552261428431"],"URL":"https:\/\/doi.org\/10.1177\/10781552261428431","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}